Becton, Dickinson and Company (BDX) to Release Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) is projected to release its Q2 2026 results before the market opens on Thursday, May 7th. Analysts expect Becton, Dickinson and Company to post earnings of $2.77 per share and revenue of $4.6678 billion for the quarter. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Parties may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.81 by $0.10. The company had revenue of $4.49 billion for the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. Becton, Dickinson and Company’s revenue was up 1.6% compared to the same quarter last year. During the same period in the previous year, the company posted $3.43 EPS. On average, analysts expect Becton, Dickinson and Company to post $13 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Becton, Dickinson and Company Stock Down 2.0%

Shares of Becton, Dickinson and Company stock opened at $146.30 on Tuesday. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The company has a market cap of $41.66 billion, a P/E ratio of 23.87, a PEG ratio of 10.65 and a beta of 0.22. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The firm has a fifty day moving average of $160.69 and a two-hundred day moving average of $181.92.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share buyback plan on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 68.52%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 1,102 shares of company stock worth $198,909 over the last ninety days. Insiders own 0.40% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cambient Family Office LLC purchased a new stake in Becton, Dickinson and Company in the 4th quarter valued at approximately $217,000. Compound Planning Inc. lifted its position in shares of Becton, Dickinson and Company by 72.9% in the fourth quarter. Compound Planning Inc. now owns 2,887 shares of the medical instruments supplier’s stock valued at $560,000 after acquiring an additional 1,217 shares in the last quarter. Invesco Ltd. lifted its position in shares of Becton, Dickinson and Company by 48.5% in the fourth quarter. Invesco Ltd. now owns 3,790,490 shares of the medical instruments supplier’s stock valued at $735,620,000 after acquiring an additional 1,237,507 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in shares of Becton, Dickinson and Company by 22.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 28,140 shares of the medical instruments supplier’s stock valued at $5,461,000 after acquiring an additional 5,106 shares during the last quarter. Finally, Andrews Advisory Associates LLC purchased a new stake in Becton, Dickinson and Company during the 4th quarter worth about $253,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

BDX has been the topic of several recent analyst reports. Argus dropped their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research report on Monday, March 23rd. The Goldman Sachs Group started coverage on Becton, Dickinson and Company in a report on Friday, April 10th. They set a “neutral” rating and a $167.00 price objective on the stock. Stifel Nicolaus increased their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Barclays assumed coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 target price on the stock. Finally, Zacks Research upgraded shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Seven equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $186.57.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.